Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Swedbank in connection with share issues in Brinova Fastigheter
Mandate

Vinge advises Swedbank in connection with share issues in Brinova Fastigheter

December 15, 2016

Vinge advises Swedbank AB (publ) in connection with two share issues in Brinova Fastigheter AB (publ), both a rights issue of shares of class B amounting to approximately SEK 210 million, as well as a share issue of shares of class B to the general public, amounting to approximately SEK 48 million, with deviation from the shareholders pre-emption rights. A prospectus was published on 29 November 2016. Brinova Fastigheter is listed on Nasdaq First North Premier.

Vinge’s team consists of Jesper Schönbeck and Nils Fredrik Dehlin.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025